Document is current
Any future updates will be listed below
-
Authors
Chifotides, Helen T. https://orcid.org/0000-0001-8044-4960
Duminuco, Andrea https://orcid.org/0000-0002-9510-4755
Torre, Elena https://orcid.org/0000-0002-8207-2969
Vetro, Calogero https://orcid.org/0000-0003-1922-5157
Harrington, Patrick https://orcid.org/0000-0001-5704-466X
Palumbo, Giuseppe A. https://orcid.org/0000-0003-1859-6319
Bose, Prithviraj https://orcid.org/0000-0002-4343-5712
-
Funding
Funding for this research was provided by:
National Institutes of Health (P30 CA016672)
- License Information
-
More Information
Article History
Accepted: 31 March 2025
First Online: 3 May 2025
Declarations
:
: A.D. received honoraria from BMS Celgene, Incyte, Janssen, AOP, Novartis and consulting fees from GSK, and AstraZeneca. P.H. received research funding from GSK, BMS, Novartis, Incyte, AOP, and Constellation and honoraria from GSK, Incyte, and Novartis. G.P. received consultancy and honoraria from AbbVie, AOP, AstraZeneca, BMS, Incyte, GSK, Morphosys, and Novartis. P.B. received research support from Incyte, BMS, CTI, a Sobi company, Morphosys (now Novartis), Kartos, Telios, Ionis, Disc, Geron, Ajax, Janssen, Sumitomo, Karyopharm, Blueprint, and Cogent; and honoraria/consulting fees from Incyte, BMS, CTI, a Sobi company, GSK, AbbVie, Morphosys (now Novartis), Novartis, PharmaEssentia, Keros, Sumitomo, Karyopharm, Geron, Morphic, Jubilant, Ono, Raythera, Ionis, Disc, Cogent, and Blueprint. P.B. is the Editor-in-Chief of Curr. Hematologic Malig. Rep. H.T.C., E.T. and C.V. declare no conflicts of interest.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
